TALKDESK
25.1.2024 17:01:28 CET | Business Wire | Press release
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced its presence at the All4Customer event in Paris from March 26 - 28, 2024. Investment in the event is part of the company’s commitment to the French market and to driving exceptional outcomes for customers and partners across the region with the power of artificial intelligence (AI)-driven customer experience.
Simon Desvergez, enterprise solutions engineer at Talkdesk, will deliver a masterclass on supercharging contact center optimization with generative AI (GenAI) on Wednesday, March 27, 2024 at 12:00 p.m. in Masterclass 6. During the 45-minute session, industry professionals will hear examples of how GenAI has automated complex customer use cases and significantly improved the quality of self-service interactions.
The All4Customer event, which attracts approximately 15,000 attendees, is the latest example of continued commitment from Talkdesk to the French market. Over the past several months, Talkdesk has exhibited at the Customer Relationship and Marketing Meetings (CRM&M) event in Cannes to gain opportunities to meet face-to-face with local customer experience (CX) leaders and held the Talkdesk Partner Academy in Paris as an investment in its partner ecosystem.
Tiago Paiva, founder and chief executive officer at Talkdesk, commented: “France continues to be a significant business driver for the company, and we’re excited for 2024 to drive further local expansion for Talkdesk. All4Customer is an important opportunity for us to connect with local CX leaders in-person and discuss the value that deploying AI cloud technology can unlock in the contact center.”
Customers such as Quadient, a global leader in cloud-based business communication software, parcel locker solutions, and mailing systems technology based in Bagneux, France, uses Talkdesk to deliver frictionless customer interactions. Before implementing Talkdesk, 40% of Quadient’s call volume in some queues consisted of simple transactions that could be self-serviced to reserve agents’ time for more complex tasks. Quadient initially developed its self-service solutions with Talkdesk, then expanded to other Talkdesk tools, including a solution to assist with agent coaching and a voice bot. As a result, Quadient doubled its self-service capabilities, increased efficiency, and created better experiences for customers and agents.
Jackie James, director of global operations at Quadient, said: “The thing that I like about Talkdesk more than anything is that they're constantly looking for ways to improve. They’re regularly deploying features that have positive impacts on CX." As one example of this, James added: “By using a voice bot [to serve Parcel Pending], we could contain a lot of simple transactions just by walking the customer through a few steps and using some integrations with our web application. We immediately saw a 60% containment rate.”
FACYLE, a key partner of Talkdesk in the French market specializing in Consulting and CTI integration, expressed excitement about the ongoing collaboration. As a crucial launch partner, FACYLE has significantly contributed to the success of Talkdesk in France. FACYLE Chief Executive Officer Francois Breuiller highlighted the consistent investment from Talkdesk in the success of their partnership and the French market.
The Talkdesk-FACYLE partnership has led to notable achievements, including successful projects with Groupe APRIL and Groupe Monnoyeur. This success is attributed to dedication from Talkdesk in providing resources, materials, and events tailored for the French audience. These efforts have accelerated momentum, empowering enterprises to enhance customer experiences through the Talkdesk AI-powered contact center solutions.
Francois Breuiller further emphasized the positive impact of the partnership, stating: "Partnering with Talkdesk for the past two years has proven that we made the right choice for a pure CCaaS solution. We successfully implemented their solution on large customers’ projects, showcasing robustness and comprehensive feature coverage.”
The All4Customer event will take place at Paris Expo Porte de Versailles, Pavilion 4, where Talkdesk will exhibit in stand F28. For more information, visit www.all4customer-paris.com.
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125676968/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom